Lifestyle

Clinical Articles iconClinical Articles

With obesity demonstrating mortality rates comparable to cigarette smoking and obstructive sleep apnoea (OSA) potentially affecting up to one billion people worldwide, the intersection of these conditions demands innovative therapeutic approaches. Recent advances in incretin-based therapies, particularly the GLP-1/GIP receptor agonist tirzepatide (Mounjaro), are revolutionising treatment for patients with concurrent obesity and OSA, offering clinically significant improvements that may challenge traditional CPAP-centric management strategies.

Upcoming Healthed Webcast

Eczema Practical Updates for General Practice

Tuesday 12th May, 7pm - 9pm AEST

Speaker

A/Prof Li-Chuen Wong

Consultant Dermatologist; Senior Specialist Visiting Medical Officer, Head, Dermatology Department, Children's Hospital at Westmead

In this talk, Associate Professor Li-Chuen Wong will outline a practical, structured approach to managing these patients. We invite you to join the next Healthed webcast.